医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PharmaCyte Biotech Releases New Interviews from Austrianova’s GMP Facility on Company’s Website

2019年06月25日 PM10:00
このエントリーをはてなブックマークに追加


 

LAGUNA HILLS, Calif.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, remains in Bangkok, Thailand, during the GMP-manufacturing process of its clinical trial material for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). Dr. Leonard Makowka, the Senior Strategic Advisor to the Chief Executive Officer and the Board of Directors, has now joined him in Bangkok, Thailand.

The company has posted several videos from the Austrianova manufacturing facility on PharmaCyte’s website.

The new videos can be seen at www.PharmaCyte.com/media and include a walkthrough of the GMP-manufacturing facility, an interview with PharmaCyte’s Chief Executive Officer and an interview with Walter H. Günzburg, the Chairman of Austrianova and PharmaCyte’s Chief Scientific Officer. Also, the company has posted a host of pictures on its Facebook page from the manufacturing facility. Those pictures can be viewed at www.Facebook.com/PharmaCyteBiotech

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190625005505/en/

CONTACT

Dr. Gerald W. Crabtree

Investor Relations:

PharmaCyte Biotech, Inc.

Investor Relations Department

Telephone: 917.595.2856

Email: Info@PharmaCyte.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 拓臻生物公布其非酒精性脂肪性肝炎(NASH)候选药物-具有肝脏选择性的法尼醇X受体(FXR)激动剂TERN-101-临床Ⅰ期试验安全性和药效学研究结果
  • Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
  • AVITA Medical Half-Year Financial Report for Fiscal 2020
  • 西联汇款启动抗击新型冠状病毒的全球援助项目
  • Jinsan Beverage of Korea Introduces Its 5 Healthy Smoothies for Spring